Kristen Castillo, MD
Obstetrics & Gynecology · Las Cruces, NMNPI 1396820734
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $280 and has fallen 67.4% since, to $91 in 2025.
Across 73 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopersurgical, Inc.$213
- Bayer$209
- AbbVie$146
- Pfizer$79
- Davol Inc.$69
- Minerva Surgical, Inc$60
- plus $453 from 18 others
What the payments were for
- Food & beverage$1,21499%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopersurgical, Inc. | 15 | $213 |
| Bayer | 13 | $209 |
| AbbVie | 9 | $146 |
| Pfizer | 4 | $79 |
| Davol Inc. | 2 | $69 |
| Minerva Surgical, Inc | 3 | $60 |
| Johnson & Johnson | 3 | $49 |
| Therapeuticsmd, Inc. | 3 | $44 |
| Gynesonics, Inc. | 2 | $40 |
| Baxter Healthcare | 2 | $35 |
| Aspira Women's Health Inc | 2 | $34 |
| Smith+Nephew | 2 | $29 |
| Shield Therapeutics Inc | 2 | $28 |
| Myovant Sciences Inc. | 1 | $23 |
| Olympus America Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Mycovia Pharmaceuticals, Inc. | 1 | $20 |
| Covidien LP | 1 | $19 |
| Organon | 1 | $19 |
| Avion Pharmaceuticals | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Coloplast | 1 | $13 |
| Pacira Pharmaceuticals Incorporated | 1 | $11 |
How this compares
$1,228 in reported general payments places this provider in the 80th percentile of 181 obstetrics & gynecology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 49 | $3,609 |
| Estradiol (Once Weekly)Estradiol | 13 | $928 |
| ProgesteroneProgesterone, Micronized | 27 | $616 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Las Cruces
- Dara SomLas Cruces$6K
- Shirley HinshawLas Cruces$5K
- Surjit MoolamallaLas Cruces$4K
- Marisa GriegoLas Cruces$3K
- Paula DelgadoLas Cruces$2K
- Joseph OrtizLas Cruces$2K
- Shahrzad TabibiLas Cruces$1K
- Elma GutierrezLas Cruces$1K
- Kristen GorbitzLas Cruces$1K
- Alyson OteroLas Cruces$449
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.